Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects

Clinical Pharmacology in Drug Development

Volumn 3, Issue 2, 2014, Pages 151-157

  Korth Bradley, Joan M ^a   Parks, Virginia ^a,d   Wagner, Frank ^b   Chalon, Stephan ^a,e   Gourley, Ian ^a,f   Matschke, Kyle ^a   Gossart, Sophie ^a   Ripp, Sharon L ^a   Fleckenstein, Lawrence ^c  

^a PFIZER INC   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF IOWA   (United States)

^d Shire France ^*  (France)

^e Shire AG   (Switzerland)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

CYP3A4; Drug interaction; Midazolam; Moxidectin; Onchocerciasis

Indexed keywords

CYTOCHROME P450 3A4; MIDAZOLAM; MOXIDECTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME SUBSTRATE; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULSE OXIMETRY; RISK ASSESSMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING;

EID: 84896046705     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.81     Document Type: Article

References (19)

1. APOC. Final Communique: Eleventh session of the Joint Action Forum. 2005. http://www.who.int/apoc/about/structure/jaf/en/index.html Accessed June 24, 2013.
2. World Health Organization. Working to overcome the global impact of neglected tropical diseases: update to WHO report on neglected tropical diseases. 2011. http://www.who.int/neglected_diseases/2010report/WHO_NTD_report_update_2011.pdf Accessed June 24, 2013.
3. Basáñez M-G, Boussinesq M. Population biology of human onchocerciasis. Philos Trans R Soc Lond B Biol Sci. 1991; 354:809-826.
4. Cotreau MM, Warren S, Ryan JL, et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol. 2003; 43:1108-1115.
5. World Health Organization. Study comparing moxidectin and ivermectin in subjects with Onchocerca volvulus infection. 2011. http://clinicaltrials.gov/ct2/show/NCT00790998 Accessed June 24, 2013.
6. Korth-Bradley J, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin. Clin Pharmacol Drug Dev. 2012; 1:32-37.
7. Korth-Bradley JM, Parks V, Chalon S, et al. The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial. Am J Trop Med Hyg. 2012; 86:122-125.
8. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. Br J Clin Pharmacol. 2001; 52:107-117.
9. European Medicines Agency. Guideline on the investigation of drug interactions 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf Accessed June 24, 2013.
10. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol. 2003; 43:1274-1282.
11. Chen YC, Hung YP, Fleckenstein L. Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies. J Pharm Biomed Anal. 2002; 29:917-926.
12. Nichols AI, Liang Y, Matschke K, et al. An evaluation of the potential of cytochrome p450 3A4-mediated drug-drug interactions with desvenlafaxine use. J Bioequiv Availab. 2013; 5:53-59.
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing and Labeling Recommendations, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf Accessed June 24, 2013.
14. World Health Organization. African Programme for Onchocerciasis Control (APOC): Treatment and control of onchocerciasis. http://www.who.int/apoc/onchocerciasis/control/en/ Accessed June 24, 2013.
15. Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother. 2011; 55:5200-5204.
16. Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989; 29:272-277.
17. Jana S, Paliwal J. Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions. Curr Protein Pept Sci. 2007; 8:619-628.
18. Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther. 2006; 79:350-361.
19. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentratiosn and effects of oral midazolam. Clin Pharmacol Ther. 1996; 9:7-13.